Learn To Psoriasis Free For Life!!!
Click Here
Anti Psoriasis Drugs
Does Psoriasis Always Lead To Psoriatic Arthritis?
For the preponderance of persons who have been diagnosed with having psoriasis, they will most likely merely need to handle the inflammatory skin pain. This condition materializes over a considerable segment of the body for a lot of people.
However for additional folks, those flaking red blotches that arise are small in number. A further grave predicament identified as psoriatic arthritis will result for about 10% of sufferers.
Psoriatic arthritis is mainly recognized by a stinging swelling of the joints. The diagnosis of this ailment is typically arrived at due to the psoriasis followed by the inflammation later. The disease generally develops in patients between the ages of 40 and 50 years old, although in truth it could happen anytime.
Very rarely does psoriatic arthritis take place when psoriasis does not. And what's more, psoriasis can progress for several years in patients ahead of the arthritis.
There is extremely little difference in who attains the disease; it turns up in both genders, in every age group, and in every race. Experts believe that psoriatic arthritis occurs because of a complexity with the body's immune system, comparable to psoriasis. They too feel that it is caused by genetics and maybe environment.
There have been certain achievements in identifying a specific gene associated with the disease. And a blood test doctors can now be prescribed to locate this gene.
The results of psoriatic arthritis involve stiffness of the joints, fever, and further severe troubles such as inflammation in the lungs or heart. Major medical problems are the results of such problems, and medical therapy of some sort is often required to avert more serious problems in the future.
Psoriatic arthritis is rather analogous to other varieties of arthritis. Because that is so, it is tough for doctors to make a correct conclusion. The best ways for them to build a proper diagnosis is to observe if the patient has a record of psoriasis. Moreover they will carry out blood tests on the patient, to aid determining what the correct disease is.
Doctors also test for infection about the swollen reddened joints to facilitate diagnose. X-rays are used to test for weakening cartilage and joints. Ultimately the doctors can build a proper diagnosis.
The treatment for psoriatic arthritis varies from person to person. There are over-the-counter drugs which could aid in lessening the pain. A number of doctors possibly will prescribe anti-rheumatic medicines to help limit the growth of the arthritis. Drugs to fight malaria have additionally been prescribed to assist in treating this disease.
But there is notwithstanding a long way to go. Much study still needs to be done, and hopefully progress will be made for the future.
About the Author
Richard Ramey administers a website that presents data dealing with psoriatic arthritis, such as how it starts, what it does, and how to treat. To learn more, please look over Rich's site at www.psoriaticarthritisaid.com.
Psoriasis - Drug Pipeline Analysis And Market Forecasts To 2015---Aarkstore Enterprise Market Research Aggregation
Description
The industry analysis specialist's new report, "Psoriasis - Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global psoriasis market. The report identifies the key trends shaping and driving the dynamism in the global psoriasis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global psoriasis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.
Estimated the psoriasis market to be worth $2.4 billion in 2008 with projected CAGR of 7.3% and projected market value to exceed $4.1 billion in 2015. The psoriasis disease market is forecast to show high growth. This growth will be driven or supported by the increased prescription rate and uptake of biologics, more emerging therapies and diverse treatment options that will be available for patients in the near future. Barriers for the psoriasis market exist in terms of low diagnosis rate. The psoriasis market has relatively high unmet need largely driven by the poor safety profile of existing products.
Found that there are over 125 molecules in various stages of the pipeline. Voclosporin, ABT-874, CF-10 are some of the late stage pipeline molecules. Orencia, Cimzia, Apremilast and INCB18424 are some of the promising therapies in the Phase II stage of the pipeline. These pipeline molecules differ in their target of action from the existing therapies. Patient perception of disease severity drives treatment-seeking behavior in the psoriasis market. New therapeutic options targeting specific mechanisms are set to reshape the psoriasis therapy. However, the current biologics have not undermined first-line topical therapy and hence there exists intensified competition between the current therapeutics and the emerging therapies. The pipeline has seen an increase in the development of emerging therapies like biologics as they have the ability to change the natural course of the disease. Emerging therapies have gained a positive perception among physicians in the maintenance of remission. There is likely to be a tremendous increase in the prescription of biologics due to increased awareness and also promising safety and efficacy results of promising therapies. The emerging therapies are likely to crowd the market and there is the possibility of price war.
Found that the current competition in the psoriasis market is becoming intense due to the increased entry of biologics. It projects that Immunex Corporation, Abbott laboratories. Biogen Idec and Centocor will remain the leading competitiors of the global psoriasis biologics market. Compared to other autoimmune disease markets, this market has witnessed a greater entry of biologics. Though only a small segment of people tend to use biologics, their launch has increased competition in the psoriasis disease market. Amgen and Wyeth's Enbrel is the market leader in the psoriasis disease market. It is followed by Abbott's Humira, Leo Pharma and Warner Chiclott's Dovonex, Centocor's Remicade, Genentech's Raptiva, Novartis's Neoral (generic), followed by Allergan's Tazorac, Biogen Idec's Fumaderm and Biogen Idec and Astellas Pharma's Amevive.
Scope of the Report
Scope of the report includes:
-
Annualized global psoriasis market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-
Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-
Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include TNF-alpha inhibitors, interleukin inhibitors, vitamin D3 analogues, topical corticosteroids, enzyme inhibitors, immunomodulatory drugs, anti-inflammatory drugs, T cell modulators and ion channel modulators.
-
Analysis of the current and future market competition in the global psoriasis market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
-
Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the psoriasis therapeutics market in the long run. Key future market players covered are Isotechnika, Can-Fite Biopharma, UCB, Celgene Corporation, Incyte, Glaxosmithkline, Bristol-Myers Squibb, Leo Pharma, Novartis and Abbott Laboratories.
-
Key topics covered include promising drugs in the pipeline, strategic competitor assessment, market psoriasis.
For more information, please visit:
Or email us at press@aarkstore.com or call +919272852585
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email : contact@aarkstore.com
Website : http://www.aarkstore.com
Blog: http://blogs.aarkstore.com/
Follow us on twitter: http://twitter.com/aarkstoredotcom
About the Author
Aarkstore Enterprise is a leading provider of business and financial information and solutions worldwide. We specialize in providing online market business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers. Our customers include more than 700 leading financial institutions, professional service firms, consulting, law and accounting firms and other corporations throughout the world.
